L 377202 

L 377202 is a peptide-drug conjugate (PDC). L 377202 consists of Doxorubicin (HY-15142A) and a prostate-specific antigen (PSA)-hydrolyzable peptide. L 377202 demonstrates strong inhibitory effects on PSA-secreting prostate cancer cells. L 377202 is promising for research of prostate cancer^[1].

1396.45

C₆₅H₈₉N₉O₂₅

207395-85-5

OC1=C2C([C@H](C[C@@](C(CO)=O)(O)C2)O[C@@]3([H])C[C@@H]([C@H](O)[C@H](C)O3)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](CCC(N)=O)NC([C@H](C4CCCCC4)NC([C@H](CO)NC([C@H](C)NC([C@H]5N(C[C@H](O)C5)C(CCCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=C(O)C6=C1C(C7=CC=CC(OC)=C7C6=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. DeFeo-Jones D, et al. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med. 2000 Nov;6(11):1248-52.  [Content Brief]